# Tris Pharma, Inc. clinical trials: 22 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 22 trials with Tris Pharma, Inc. as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Tris Pharma, Inc.: 22 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/tris-pharma-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 22
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 22 newest of 22, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 9, 2024 | NCT06545097 | A Study of Cebranopadol for the Treatment of Acute Pain After Abdominoplasty | Tris Pharma, Inc. | Phase 3 | Completed | Acute Pain | 279 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06545097) |
| June 11, 2024 | NCT06453265 | A Study to Assess the Abuse Potential of Intranasal Cebranopadol | Tris Pharma, Inc. | Phase 1 | Completed | Abuse, Drug | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06453265) |
| May 21, 2024 | NCT06423703 | A Study of Cebranopadol for the Treatment of Acute Pain After Bunionectomy | Tris Pharma, Inc. | Phase 3 | Completed | Acute Pain | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06423703) |
| August 8, 2022 | NCT05491785 | Cebranopadol Effects on Ventilatory Drive, Central Nervous System (CNS) and Pain. | Tris Pharma, Inc. | Phase 1 | Completed | Pain | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05491785) |
| February 25, 2022 | NCT05256108 | Assessment of Abuse Potential of Cebranopadol in Humans | Tris Pharma, Inc. | Phase 1 | Completed | Human Abuse Potential | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05256108) |
| July 22, 2019 | NCT04027361 | Amphetamine Extended Release Tablets and Driving Performance in Subjects With Attention Deficit/Hyperactivity Disorder (ADHD) | Tris Pharma, Inc. | Phase 2 | Completed | ADHD | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04027361) |
| May 21, 2019 | NCT03958123 | Evaluation of the Effects of Multiple Doses of Cebranopadol on the Electrical Activity of the Heart in Healthy Subjects | Tris Pharma, Inc. | Phase 1 | Completed | Prolonged QTc Interval, Pharmacokinetic | 171 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03958123) |
| March 20, 2019 | NCT03882762 | A Clinical Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of Cebranopadol | Tris Pharma, Inc. | Phase 1 | Completed | Pharmacokinetic | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03882762) |
| February 8, 2019 | NCT03834766 | Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD | Tris Pharma, Inc. | Phase 3 | Completed | ADHD | 130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03834766) |
| November 29, 2018 | NCT03757559 | A Trial to Evaluate the Abuse Potential of 3 Doses of GRT6005 in Adult Non-dependent Recreational Opioid Users | Tris Pharma, Inc. | Phase 1 | Completed | Abuse, Drug | 226 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03757559) |
| August 1, 2018 | NCT03610464 | Pharmacokinetic Study of DYANAVEL XR (Amphetamine) Extended-release Oral Suspension, in Children Aged 4 to 5 Years | Tris Pharma, Inc. | Phase 4 | Completed | Attention Deficit Hyperactivity Disorder | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03610464) |
| March 23, 2017 | NCT03088267 | Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children With ADHD: A Laboratory School Study | Tris Pharma, Inc. | Phase 3 | Completed | Attention Deficit Hyperactivity Disorder | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03088267) |
| March 11, 2014 | NCT02083783 | TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD) | Tris Pharma, Inc. | Phase 3 | Completed | Attention Deficit Disorder With Hyperactivity | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02083783) |
| January 9, 2014 | NCT02031432 | CORAL XT - Open-label Extension Trial of the CORAL Trial | Tris Pharma, Inc. | Phase 3 | Completed | Pain, Neoplasms, Chronic Pain | 76 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02031432) |
| October 17, 2013 | NCT01964378 | CORAL - Cebranopadol Versus Morphine Prolonged-release in Patients With Chronic Moderate to Severe Pain Related to Cancer | Tris Pharma, Inc. | Phase 3 | Terminated | Pain, Neoplasms, Chronic Pain | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01964378) |
| September 11, 2013 | NCT01939366 | Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the Nerves | Tris Pharma, Inc. | Phase 2 | Completed | Chronic Pain, Diabetic Neuropathies, Diabetes Mellitus | 699 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01939366) |
| November 12, 2012 | NCT01725087 | Efficacy and Safety of GRT6005 in Patients With Chronic Low Back Pain. | Tris Pharma, Inc. | Phase 2 | Completed | Low Back Pain | 1,089 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01725087) |
| October 18, 2012 | NCT01709214 | Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee Pain | Tris Pharma, Inc. | Phase 2 | Completed | Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee | 619 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01709214) |
| May 23, 2011 | NCT01357837 | Assessment of GRT6005 in Painful Osteoarthritis of the Knee | Tris Pharma, Inc. | Phase 2 | Completed | Osteoarthritis of the Knee | 207 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01357837) |
| May 4, 2011 | NCT01347671 | Safety and Efficacy of GRT6005 in Pain Due to Diabetic Polyneuropathy | Tris Pharma, Inc. | Phase 2 | Completed | Pain, Diabetic Neuropathies | 189 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01347671) |
| April 8, 2009 | NCT00878293 | Painful Diabetic Polyneuropathy Trial With a New Centrally Acting Analgesic | Tris Pharma, Inc. | Phase 2 | Completed | Diabetic Polyneuropathy | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00878293) |
| March 31, 2009 | NCT00872885 | Bunionectomy Trial With GRT6005 | Tris Pharma, Inc. | Phase 2 | Completed | Post Operative Pain | 258 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00872885) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 6 |
| Phase 2 | 8 |
| Phase 3 | 7 |
| Phase 4 | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 21 |
| Terminated | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Pain | 7 |
| Attention Deficit Disorder with Hyperactivity | 5 |
| Chronic Pain | 4 |
| Diabetic Neuropathies | 3 |
| Substance-Related Disorders | 2 |
| Diabetes Mellitus | 2 |
| Agnosia | 2 |
| Acute Pain | 2 |
| Neoplasms | 2 |
| Cancer Pain | 2 |
| Osteoarthritis | 1 |
| Bronchiolitis Obliterans Syndrome | 1 |
| Arthritis | 1 |
| Neuralgia | 1 |
| Osteoarthritis, Knee | 1 |
| Hypercapnia | 1 |
| Low Back Pain | 1 |
| Pain, Postoperative | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Engineering schools in the United States](https://specstream.ai/data/businesses/engineering-schools/united-states)
- [Vehicle shipping companies in the United States](https://specstream.ai/data/businesses/vehicle-shipping-companies/united-states)
- [Life insurance agencies in the United States](https://specstream.ai/data/businesses/life-insurance-agencies/united-states)
- [Cafes in the United States](https://specstream.ai/data/businesses/cafes/united-states)
- [Refinishing companies in the United States](https://specstream.ai/data/businesses/refinishing-companies/united-states)
- [Food and beverage distributors in the United States](https://specstream.ai/data/businesses/food-and-beverage-distributors/united-states)
